Suppr超能文献

用于急性哮喘β受体激动剂治疗的储雾罐与雾化器对比

Holding chambers versus nebulisers for beta-agonist treatment of acute asthma.

作者信息

Cates C J, Rowe B H, Bara A

机构信息

Manor View Practice, Bushey Health Centre, London Road, Bushey, Watford, Hertfordshire, UK, WD2 2NN.

出版信息

Cochrane Database Syst Rev. 2002(2):CD000052. doi: 10.1002/14651858.CD000052.

Abstract

BACKGROUND

In acute asthma inhaled beta-agonists are often administered to relieve bronchospasm by wet nebulisation, but some have argued that metered-dose inhalers with a holding chamber (spacer) can be equally effective. In the community setting nebulisers are more expensive, require a power source and need regular maintenance.

OBJECTIVES

There is controversy as to whether wet nebulisers are better than metered dose inhalers with holding chambers to deliver beta2-agonist medications for acute asthma. Comparisons of hospital and home use are also of interest. The objective of this review was to assess the effects of holding chambers compared to nebulisers for the delivery of beta2-agonists for acute asthma.

SEARCH STRATEGY

We searched the Cochrane Airways Group trials register and the Cochrane Controlled Trials Register.

SELECTION CRITERIA

Randomised trials in adults and children (from two years of age) with asthma, where holding chamber beta2-agonist delivery was compared with wet nebulisation.

DATA COLLECTION AND ANALYSIS

Two reviewers independently applied study inclusion criteria (one reviewer for the first version of the review), extracted the data and assessed trial quality. Missing data were obtained from the authors or estimated.

MAIN RESULTS

This review has been updated in 2001 to include 4 new trials and has now analysed 880 children and 444 adults included in 21 trials. Method of delivery of beta2-agonist did not appear to affect hospital admission rates. In adults, the relative risk of admission for holding chamber versus nebuliser was 0.88 (95% confidence interval 0.56 to 1.38). The relative risk for children was 0.65 (95% confidence interval 0.4 to 1.06). One study in children found a significantly shorter length of stay in the emergency department when the holding chamber was used, with a weighted mean difference of -0.62 hours, 95% confidence interval -0.84 to -0.40 hours. Adults' length of stay in the emergency department was similar for the two delivery methods. Peak flow and forced expiratory volume were also similar for the two delivery methods. Pulse rate was lower for holding chamber in children, weighted mean difference -7.8% baseline (95% confidence interval -10.2 to -5.3).

REVIEWER'S CONCLUSIONS: Metered-dose inhalers with holding chamber produced outcomes that were at least equivalent to nebuliser delivery. Holding chambers may have some advantages compared to nebulisers for children with acute asthma.

摘要

背景

在急性哮喘治疗中,吸入性β-受体激动剂常通过湿化雾化给药以缓解支气管痉挛,但一些人认为带有储雾罐(储物器)的定量吸入器同样有效。在社区环境中,雾化器更昂贵,需要电源且需定期维护。

目的

对于在急性哮喘中使用β2-受体激动剂时,湿化雾化器是否优于带有储雾罐的定量吸入器存在争议。医院使用和家庭使用的比较也备受关注。本综述的目的是评估与雾化器相比,储雾罐在急性哮喘中递送β2-受体激动剂的效果。

检索策略

我们检索了Cochrane Airways Group试验注册库和Cochrane对照试验注册库。

选择标准

针对患有哮喘的成人和儿童(两岁及以上)的随机试验,其中将使用储雾罐递送β2-受体激动剂与湿化雾化进行比较。

数据收集与分析

两名综述作者独立应用研究纳入标准(一名综述作者负责综述的第一版),提取数据并评估试验质量。缺失数据从作者处获取或进行估算。

主要结果

本综述于2001年更新,纳入了4项新试验,目前已分析了21项试验中的880名儿童和444名成人。β2-受体激动剂的给药方式似乎并未影响住院率。在成人中,使用储雾罐与雾化器相比的住院相对风险为0.88(95%置信区间0.56至1.38)。儿童的相对风险为0.65(95%置信区间0.4至1.06)。一项针对儿童的研究发现,使用储雾罐时急诊室停留时间显著缩短,加权平均差为-0.62小时,95%置信区间-0.84至-0.40小时。两种给药方式下成人在急诊室的停留时间相似。两种给药方式下的峰值流速和用力呼气量也相似。儿童使用储雾罐时脉搏率较低,加权平均差为低于基线7.8%(95%置信区间-10.2至-5.3)。

综述作者结论

带有储雾罐的定量吸入器产生的结果至少与雾化给药相当。对于急性哮喘儿童,储雾罐可能比雾化器具有一些优势。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验